our Thank you, to provide Ugur. speak today to I'm update. everyone with delighted and pipeline
Slide our COVID-XX XX. Starting with vaccine.
as and Sars-Cov-X vaccinations, to vaccine there and for that the and boosting especially severe COVID-XX demand groups. risk continues, evolve expect for We be immunocompromised at-risk persisting death of disease continues will and
the of COVID-XX account and globally for lineages, X, Omicron circulating case SARS-CoV-X including SARS-CoV-X the distant BA from are and energetically strain. currently So majority X, XBB original prior sub-lineages Omicron
bivalent have against some protection outcomes XBB in and neutralization vaccines COVID-XX. earlier further other. range adapted related Although, protection lineages Omicron similar reduced currently have BA severe from to against circulating Omicron COVID-XX. Evidence improved lineage suggests sub-lineages X, to but of comparison matched provide a symptomatic each better can neutralization that X profiles XBB vaccine have disease viruses to
here. help season, differ are the vaccines May, during Despite EMA COVID-XX in sequence of targeting COVID-XX guidance expected to health winter XBB.X.X to and that the provided other and sub-lineages and Omicron and updated only hospitalizations In may two upcoming fall mutations XBB.X increase. protection highlighting when authorities maintain case XBB.X.XX against highlighted rates
our months manufacture an for for Products EMT Biologicals XBB.X.X COVID-XX vaccine monovalent XXXX seasons. Committee, to Vaccines Advisory the VRBPAC, Omicron of the We adapted monovalent order. guidance FDA's fall the of and issued and Omicron Also six FDA and regulatory adapted and the and to individuals and Pfizer Related XXXX COVID-XX submitted winter recommending vaccine applications age for XBB.X.X
guidance may against include suggesting to XBB regulatory BA.X-X bivalent generate strain COVID-XX improved responses monovalent the Following vaccine. circulating sub-lineages the that compared changes, vaccine on data XBB.X.X current requirements Omicron adapted COVID-XX from the authorities Omicron for adapted applications
effectiveness we as monovalent Moving Pfizer mice. our a and to primary XX, potential Slide an XBB.X.X of partner adapted in and vaccine booster Omicron series tested
adapted XBB.X.X the a vaccine you the BA.X-X Here fourth response COVID-XX vaccine. group bivalent dose. see the mice booster And a immunized vaccine as new adapted again received monovalent after received BA.X-X vaccine adapted of as bivalent in doses fourth antibody group two our COVID-XX as with One other the of mice original neutralizing dose. Omicron
with broad submissions neutralization regulatory vaccine progress well-prepared to increase You four COVID-XX that to we cross-neutralizing US-FDA, approved in to early XBB.X.X, several can EMA, XBB.X.X variant the the is fall to if vaccine COVID-XX We adapted year. compared authorities monovalent an pre-vaccinated five-fold antibody in to vaccine, induce made sub-lineages. titers see when against XBB as and against multiple and this adapted regulatory vaccine Omicron other towards are launch dose XBB.X.X variants vaccine significant XBB monovalent adapted the monovalent of related of potential the a last has indicating four season's bivalent setting
Moving to our pipeline. oncology
stage our advancements sensitive, is Slide with immunotherapy Let XXX and the clinical first cancer. approximately pH anti-CTLAX of me metastatic Phase expected the in our of BNTXXX depicted non-small which strategic non-small pipeline, initiation X the mode resistant quarter, marks antibody pivotal XX. randomized on lung in Phase enroll second cell is collaboration is OncoCX. cancer evaluating second the X broader context our trial put with into trial landmark In patients action The distinctive of lung pipeline cell to with quarter the our
cell trial in third is and The a granted metastatic and X/X the checkpoint a added is X/X for pipeline. based for resistant currently ADC in oncology in our tumors. Phase efficacy we and non-small on designation clinical XXXX collaboration our lung to cancer. trial solid expanded with Further, safety follows FDA Fast-Track monotherapy Phase inhibitor, immune initiation for data Duality DB-XXXX
cancer from lung news have antigen I BNTXXX, Then based candidate. our FixVac
monotherapy with trial treatment end a lung Together naive in we squamous our patients BNTXXX alone multi-center cemiplimab cemiplimab expression non-squamous X cell cancer The Regeneron, open-label in at stage least the Xc, with dosed XX% evaluate or of patients stage for non-small second Phase-X stage in with combination randomized first has study. with PD-LX July. on with Xb, patient partner will its BNTXXX
alone clinical X and have the PD-X are combination safety, of inhibitor is therapy in chemotherapy. for have or cemiplimab prior tolerability platinum-based patients not with in who BNTXXX received Phase efficacy and preliminary trial patients in The and combination who chemotherapy with PD-X inhibitor treatment on with in eligible BNTXXX prior to ongoing and docetaxel progressed evaluate
with are to planning trials partners, imminently. our several start We
Nature. safety autogene adjuvant planned recently in combination cancer Firstly, is The in building FOLFIRINOX standard modified of patients evaluating the cevumeran our on candidate with modified that resectable as BNTXXX, setting FOLFIRINOX Phase with the to trial X we reported individualized autogene and X cevumeran, compared our Phase atezolizumab Genentech, PDAC with efficacy partner vaccine compelling and alone. in with in of data care
will study ADC comers and novel The melanoma a DNA non-small antibody to the cancer, all to X part, esophageal Bio. recommended topoisomerase-X BNTXXX is X in with is via Phase part of conjugated cell Phase cancer, prostate lung Second, developed Phase the cleavable humanized by cancer, evaluate aim In Duality X second and another and inhibitor evaluate trial efficacy linker. planned the expansion our in safety dose start we dose. and determine a the tumors. to safety solid other small cell a
of and regulatory depleting the associated antibody of CTLAX process targeting of endosomes. this from the antibody primarily autoimmunity. to slides, CTLAX of summarize On works On cell Annual recently ASCO of programs binding Physiologically, continuously their starting the the tumor-specific T-cells Meeting. the between is next couple recycles suppression I our data by by Interruption BNTXXX/ONC-XXX surface the Slide a three XX, at development presented want with with thus of and immunity.
of are stronger events antibody CTLAX the in approved of designed and major antibodies effects. the CTLAX adverse molecule BNTXXX degradation and checkpoint from molecule recycling dissociates therapeutic CTLAX that immune-related thus in and limitation important molecule. Autoimmunity both promoting and immune-related allows adverse disrupt immune endosomes lysosomal this effect by contrast a recycling for the less anti-CTLAX normal the cancer of is
was dose BNTXXX in IO-IO with single which no escalation that reported was toxicities. adverse Phase limiting the considered determined The than MTD is lower comparable Preliminary XX%, event dose immune-related Severe being reached. recommended was agent data for X showed combo rate XXmg/kg well-tolerated is what dose combinations. without to be pembrolizumab X with grade
monotherapy a Xmg/kg. promising. as patients platinum and solid dosed in efficacy of BNTXXX The longer to for combination for with X was Early is duration in well-tolerated ipilimumab. multiple recommended combination were compared, and safety the is profile example, data for cancer combination to as in and appears Overall, dosing resistant tumors ovarian pembrolizumab treatment allow Phase dose and monotherapy higher
of Slide XX, X/X that previous we inhibition BNTXXX The status slides. with OncoCX, data to inhibitors. failed The that several including ECOG with the our responded cell lung had objective immune colleagues XX%. in treatment, BNTXXX majority presented XX investigating in XX% Phase lines multiple from immune X. had was progressed patients study disease control about on cancer non-small response metastatic checkpoint and of from previously of patients an rate Patients lesion was rate checkpoint
this related ALT/AST adverse managable colitis, included when tolerability in increase, at In hepatitis. X shown has Immune and patients three cohort, Grade mediated observed and followed dosed weeks. XX% X, immune of safety mg/kg immune were X with XXmg/kg events and BNTXXX twice and every of
the development findings BNTXXX cancer non-small X XXX. further of Our in lung the cell PRESERVE Phase support study in
believe Slide from our the for of next clinical benefits oncology. first ADC. will second we BNTXXX multiple that is Duality together ADCs inhibitor become a BNTXXX, presentation clinical via linker. topoisomerase-X was used antibody XX, of modality with our our backbone a a and for proprietary shown targeting comprised colleagues Approved at combos covalently broadly mid-term data and ASCO DNA ADCs as about to activity Bio in linked generation cancer and HERX-targeting in our types our have anti-tumor HERX cleavable
window and safer ADC trastuzumab compared incubated outstanding and benefit. T-DMX to potential stability. for improved plasma human distracted Preclinical when efficacious and HERX trastuzumab monkey, data further HERX therapeutic has to BNTXXX significantly as BNTXXX ratio. high rat, plasma ADCs, emtansine, More or deruxtecan add for a DS-XXXXA toxicity drug-to-antibody And anti approved with clinical may demonstrated analogs respectively. example, lung regarding
and showed Altogether, systemic and animal Pharmacokinetic of xenografted inhibited into of targeted tumor of negative cell analysis BNTXXX cultures, In models the proliferation the toxin. models. BNTXXX monkeys vivo types, HERX pharmacodynamic systemic stability studies of delivery cell in showed the HERX tissue. positive toxicity toxin in result a of mixed In its BNTXXX bystander mouse rapid of maintenance of properties demonstrating in clearance effect. in and superior these reduction efficacy and both
mutation. metastatic tumors. designation clinical or for evaluated the patients advanced HERX via IHC HERX Slide XX, HERX by solid ISH Phase NGS with FDA majority patients a IHC HERX the study for Fast-Track X+ or of in being program The is of received level X+. status identified via from or a The or is has expression pretreated had targetable and enrolling trial. X/X is expression amplification HERX
Anti-tumor antibody therapy. in the HERX low breast patients, disease patients, activity rate also anti-tumor breast of with is and therapy, including cancer in of control disease ADCs, cancer. endometrial In cancer BNTXXX the HERX HERX such anti-HERX response control pretreated positive median We expressing rate showed observed colorectal XX%, rate preliminary heavily ovarian other is treatments, and the objective prior seven TKI XX%. tumor patients XX%, activity systemic a is rate In cancer non-breast as types anti is response HERX was XX%. cancer anti-HERX cancer, objective
are Grade so was in data patients and treated expect ongoing were recombinant HERX of occurred and X adverse with year. at cohorts out Responses dose of disease treated two observed dose X levels tumor Expansion XX this BNTXXX we all in-patients status. were in expression well-tolerated further events manageable different Phase patients. Interstitial and patients lung far. selected
CAR-T finally, we CAR The presented a BNTXXX. but cell therapy product we engraftment To CLDNX carcino-embryonic it is ideal is healthy high sensitive targeting XX, We cell medical vaccine of highly second and persistence, candidate tissues, our developed highly short. RNA an with Slide CAR-T specificity. cell co-developed as on target in high a [indiscernible] cancers. for for many improve CARVac expressed need absent generation CLDNX data in antigen amplifying
we the on of to enhanced function be In CARVac body-wide cells goal technology cells particularly is and based RNA of persistence mRNA have vaccine nucleoside mediates uridine, CAR-T repeated further animal is relevant. delivery that antigen can our and lipoplex nano-particulate vaccine CARVac, compartments administration CAR-T encodes resident [indiscernible] RNA shown lymphoid by The that studies, to presenting keep Claudin-X. at effector a cells.
of and multiple with CAR-Ts the controlled tumor folded CAR-T In and stimulation enabled target doses natively display cell the were target expansion mediated the administered. presenting T-cell along preclinical antigen translated higher in-vivo of memory cells if even induced sub-therapeutic phenotype, sensitivity, models, cells, control on CAR protein
of activity more X+ process. with has tumor have with combination the at tolerability, escalation signs cancer CAR-T manageable XX% the a defined cells in cells clinical a with and testing occurred safety, conferences cells presented CARVac than types various highly study as activity dose of levels are data CAR-T dose cells Claudin-X Dose fixed X+ CARVac to of encouraging schedule six the derived escalation safety CAR-T completed we in for from with We bifurcated and and patients various in and manufacturing increasing And intensity. the been past. in of that positive of manual
a XX our detected Claudin-X of a with as treated been CAR-T reflecting the X have with level XX% XX X and product far patients the namely our XX, Objective levels. at as times in CARVac patients XX% cells dose so escalation manufactured available patients the scalable CAR-T were response profile two, Slide XX CAR-T process. in DLTs No for observed cohort treated have safety subsequent rate the eight of for dose well version was been automated well-tolerated, first cells. to
to we ovarian cancer dominated the germ escalation, tumors, patients responding. first-dose cell Next which observed
tumors, this initiate for an transform multiple pivotal Designation year. BNTXXX, plan This a our year. expecting Phase Prime remains key next read-out to a data towards EMA. we as we the pipeline received programs the and we the for have in year, pipeline X are advance a strategic Once by Advancing to dose priority plan our which stage. trial determined pivotal recommended has we germ We cell already additional later
I to Jens our presentation pass the CFO, will now Holstein.
